Fideuram Intesa Sanpaolo Private Banking S.P.A. Purchases Shares of 9,357 Glaukos Corporation $GKOS

Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in Glaukos Corporation (NYSE:GKOS) in the first quarter, Holdings Channel.com reports. The institutional investor acquired 9,357 shares of the medical instruments supplier’s stock, valued at approximately $1,007,000.

Other institutional investors also recently modified their holdings of the company. Wellington Management Group LLP increased its position in shares of Glaukos by 10.4% during the third quarter. Wellington Management Group LLP now owns 3,580,670 shares of the medical instruments supplier’s stock valued at $292,004,000 after purchasing an additional 336,266 shares during the period. Primecap Management Co. CA lifted its position in Glaukos by 49.8% in the fourth quarter. Primecap Management Co. CA now owns 3,376,928 shares of the medical instruments supplier’s stock worth $381,289,000 after purchasing an additional 1,123,140 shares during the period. Janus Henderson Group PLC lifted its position in Glaukos by 183.4% in the fourth quarter. Janus Henderson Group PLC now owns 3,018,787 shares of the medical instruments supplier’s stock worth $340,855,000 after purchasing an additional 1,953,578 shares during the period. State Street Corp boosted its stake in Glaukos by 0.9% during the fourth quarter. State Street Corp now owns 2,122,402 shares of the medical instruments supplier’s stock worth $239,640,000 after buying an additional 18,040 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its stake in Glaukos by 3.5% during the second quarter. Ameriprise Financial Inc. now owns 1,999,252 shares of the medical instruments supplier’s stock worth $206,503,000 after buying an additional 68,497 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Insider Activity

In related news, COO Joseph E. Gilliam sold 19,573 shares of the stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $143.54, for a total transaction of $2,809,508.42. Following the completion of the sale, the chief operating officer owned 73,419 shares in the company, valued at $10,538,563.26. This trade represents a 21.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Leana Wen sold 1,700 shares of Glaukos stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $143.35, for a total transaction of $243,695.00. Following the transaction, the director directly owned 19,739 shares of the company’s stock, valued at $2,829,585.65. This represents a 7.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 41,273 shares of company stock worth $5,832,003 in the last quarter. 5.90% of the stock is owned by company insiders.

Glaukos Stock Performance

Shares of NYSE:GKOS opened at $147.49 on Friday. The business’s fifty day moving average price is $129.31 and its two-hundred day moving average price is $119.35. Glaukos Corporation has a fifty-two week low of $73.16 and a fifty-two week high of $148.62. The stock has a market capitalization of $8.66 billion, a price-to-earnings ratio of -44.97 and a beta of 0.75. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.43 and a quick ratio of 4.73.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.12. The company had revenue of $150.57 million during the quarter, compared to analysts’ expectations of $137.00 million. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The business’s revenue was up 41.2% on a year-over-year basis. During the same period last year, the business earned ($0.22) earnings per share. As a group, analysts predict that Glaukos Corporation will post -0.57 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on GKOS. JPMorgan Chase & Co. increased their price objective on shares of Glaukos from $120.00 to $140.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Needham & Company LLC lifted their target price on shares of Glaukos from $136.00 to $150.00 and gave the company a “buy” rating in a research report on Wednesday, June 17th. BTIG Research reissued a “buy” rating and issued a $162.00 target price on shares of Glaukos in a research note on Wednesday, June 10th. Stifel Nicolaus set a $170.00 price target on shares of Glaukos in a research report on Thursday, April 30th. Finally, Piper Sandler reissued an “overweight” rating and issued a $165.00 price target on shares of Glaukos in a research report on Wednesday. Twelve equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $149.17.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.